{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T16:16:05Z","timestamp":1785168965892,"version":"3.55.0"},"reference-count":41,"publisher":"Archives of Pathology and Laboratory Medicine","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,10,1]]},"abstract":"<jats:sec>\n                    <jats:title>Context.\u2014<\/jats:title>\n                    <jats:p>The performance of laboratory testing has recently come under increased scrutiny as part of important and ongoing debates on regulation and reimbursement. To address this critical issue, this study compares the performance of assay methods, using either commercial kits or assays designed and implemented by single laboratories (\u201chome brews\u201d), including next-generation sequencing methods, on proficiency testing provided by the College of American Pathologists Molecular Oncology Committee.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective.\u2014<\/jats:title>\n                    <jats:p>To compare the performance of different assay methods on College of American Pathologists proficiency testing for variant analysis of 3 common oncology analytes: BRAF, EGFR, and KRAS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design.\u2014<\/jats:title>\n                    <jats:p>There were 6897 total responses across 35 different proficiency testing samples interrogating 13 different variants as well as wild-type sequences for BRAF, EGFR, and KRAS. Performance was analyzed by test method, kit manufacturer, variants tested, and preanalytic and postanalytic practices.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.\u2014<\/jats:title>\n                    <jats:p>Of 26 reported commercial kits, 23 achieved greater than 95% accuracy. Laboratory-developed tests with no kit specified demonstrated 96.8% or greater accuracy across all 3 analytes (1123 [96.8%] acceptable of 1160 total responses for BRAF; 848 [97.5%] acceptable of 870 total responses for EGFR; 942 [97.0%] acceptable of 971 total responses for KRAS). Next-generation sequencing platforms (summed across all analytes and 2 platforms) demonstrated 99.4% accuracy for these analytes (165 [99.4%] acceptable of 166 total next-generation sequencing responses). Slight differences in performance were noted among select commercial assays, dependent upon the particular design and specificity of the assay. Wide differences were noted in the lower limits of neoplastic cellularity laboratories accepted for testing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions.\u2014<\/jats:title>\n                    <jats:p>These data demonstrate the high degree of accuracy and comparable performance across all laboratories, regardless of methodology. However, care must be taken in understanding the diagnostic specificity and reported analytic sensitivity of individual methods.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.5858\/arpa.2018-0396-cp","type":"journal-article","created":{"date-parts":[[2019,4,10]],"date-time":"2019-04-10T09:22:17Z","timestamp":1554888137000},"page":"1203-1211","source":"Crossref","is-referenced-by-count":14,"title":["Performance Comparison of Different Analytic Methods in Proficiency Testing for Mutations in the BRAF, EGFR, and KRAS Genes: A Study of the College of American Pathologists Molecular Oncology Committee"],"prefix":"10.5858","volume":"143","author":[{"given":"Joel T.","family":"Moncur","sequence":"first","affiliation":[{"name":"From the Office of the Director, The Joint Pathology Center, Silver Spring, Maryland (Dr Moncur); the Department of Pathology, St Joseph Mercy Hospital, Ypsilanti, Michigan (Dr Bartley); the Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha (Dr Bridge); the Department of Pathology, University Health Network, University of Toronto, Toronto, Ontario, Canada (Dr"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela N.","family":"Bartley","sequence":"additional","affiliation":[{"name":"From the Office of the Director, The Joint Pathology Center, Silver Spring, Maryland (Dr Moncur); the Department of Pathology, St Joseph Mercy Hospital, Ypsilanti, Michigan (Dr Bartley); the Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha (Dr Bridge); the Department of Pathology, University Health Network, University of Toronto, Toronto, Ontario, Canada (Dr"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia A.","family":"Bridge","sequence":"additional","affiliation":[{"name":"From the Office of the Director, The Joint Pathology Center, Silver Spring, Maryland (Dr Moncur); the Department of Pathology, St Joseph Mercy Hospital, Ypsilanti, Michigan (Dr Bartley); the Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha (Dr Bridge); the Department of Pathology, University Health Network, University of Toronto, Toronto, Ontario, Canada (Dr"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Kamel-Reid","sequence":"additional","affiliation":[{"name":"From the Office of the Director, The Joint Pathology Center, Silver Spring, Maryland (Dr Moncur); the Department of Pathology, St Joseph Mercy Hospital, Ypsilanti, Michigan (Dr Bartley); the Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha (Dr Bridge); the Department of Pathology, University Health Network, University of Toronto, Toronto, Ontario, Canada (Dr"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander J.","family":"Lazar","sequence":"additional","affiliation":[{"name":"From the Office of the Director, The Joint Pathology Center, Silver Spring, Maryland (Dr Moncur); the Department of Pathology, St Joseph Mercy Hospital, Ypsilanti, Michigan (Dr Bartley); the Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha (Dr Bridge); the Department of Pathology, University Health Network, University of Toronto, Toronto, Ontario, Canada (Dr"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal I.","family":"Lindeman","sequence":"additional","affiliation":[{"name":"From the Office of the Director, The Joint Pathology Center, Silver Spring, Maryland (Dr Moncur); the Department of Pathology, St Joseph Mercy Hospital, Ypsilanti, Michigan (Dr Bartley); the Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha (Dr Bridge); the Department of Pathology, University Health Network, University of Toronto, Toronto, Ontario, Canada (Dr"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.","family":"Long","sequence":"additional","affiliation":[{"name":"From the Office of the Director, The Joint Pathology Center, Silver Spring, Maryland (Dr Moncur); the Department of Pathology, St Joseph Mercy Hospital, Ypsilanti, Michigan (Dr Bartley); the Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha (Dr Bridge); the Department of Pathology, University Health Network, University of Toronto, Toronto, Ontario, Canada (Dr"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason D.","family":"Merker","sequence":"additional","affiliation":[{"name":"From the Office of the Director, The Joint Pathology Center, Silver Spring, Maryland (Dr Moncur); the Department of Pathology, St Joseph Mercy Hospital, Ypsilanti, Michigan (Dr Bartley); the Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha (Dr Bridge); the Department of Pathology, University Health Network, University of Toronto, Toronto, Ontario, Canada (Dr"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex J.","family":"Rai","sequence":"additional","affiliation":[{"name":"From the Office of the Director, The Joint Pathology Center, Silver Spring, Maryland (Dr Moncur); the Department of Pathology, St Joseph Mercy Hospital, Ypsilanti, Michigan (Dr Bartley); the Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha (Dr Bridge); the Department of Pathology, University Health Network, University of Toronto, Toronto, Ontario, Canada (Dr"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Rimm","sequence":"additional","affiliation":[{"name":"From the Office of the Director, The Joint Pathology Center, Silver Spring, Maryland (Dr Moncur); the Department of Pathology, St Joseph Mercy Hospital, Ypsilanti, Michigan (Dr Bartley); the Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha (Dr Bridge); the Department of Pathology, University Health Network, University of Toronto, Toronto, Ontario, Canada (Dr"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul G.","family":"Rothberg","sequence":"additional","affiliation":[{"name":"From the Office of the Director, The Joint Pathology Center, Silver Spring, Maryland (Dr Moncur); the Department of Pathology, St Joseph Mercy Hospital, Ypsilanti, Michigan (Dr Bartley); the Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha (Dr Bridge); the Department of Pathology, University Health Network, University of Toronto, Toronto, Ontario, Canada (Dr"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Vasalos","sequence":"additional","affiliation":[{"name":"From the Office of the Director, The Joint Pathology Center, Silver Spring, Maryland (Dr Moncur); the Department of Pathology, St Joseph Mercy Hospital, Ypsilanti, Michigan (Dr Bartley); the Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha (Dr Bridge); the Department of Pathology, University Health Network, University of Toronto, Toronto, Ontario, Canada (Dr"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette S.","family":"Kim","sequence":"additional","affiliation":[{"name":"From the Office of the Director, The Joint Pathology Center, Silver Spring, Maryland (Dr Moncur); the Department of Pathology, St Joseph Mercy Hospital, Ypsilanti, Michigan (Dr Bartley); the Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha (Dr Bridge); the Department of Pathology, University Health Network, University of Toronto, Toronto, Ontario, Canada (Dr"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3906","published-online":{"date-parts":[[2019,4,10]]},"reference":[{"key":"2020081300265724900_i1543-2165-143-10-1203-b01","article-title":"AACC warns of \u201cextraneous\u201d LDT oversight","author":"College of American Pathologists","year":"2015","journal-title":"CAP Today"},{"key":"2020081300265724900_i1543-2165-143-10-1203-b02","doi-asserted-by":"crossref","first-page":"2374289517708309","DOI":"10.1177\/2374289517708309","article-title":"The case for laboratory developed procedures: quality and positive impact on patient care","volume":"4","author":"Kaul","year":"2017","journal-title":"Acad Pathol"},{"key":"2020081300265724900_i1543-2165-143-10-1203-b03","article-title":"Is lab testing the \u201cWild West\u201d of medicine?","author":"Burton","year":"2015","journal-title":"Wall Street Journal"},{"issue":"7","key":"2020081300265724900_i1543-2165-143-10-1203-b04","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1001\/jama.2014.18145","article-title":"Genetic testing and FDA regulation: overregulation threatens the emergence of genomic medicine","volume":"313","author":"Evans","year":"2015","journal-title":"JAMA"},{"issue":"7","key":"2020081300265724900_i1543-2165-143-10-1203-b05","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1001\/jama.2014.18135","article-title":"FDA regulation of laboratory-developed diagnostic tests: protect the public, advance the science","volume":"313","author":"Sharfstein","year":"2015","journal-title":"JAMA"},{"issue":"6","key":"2020081300265724900_i1543-2165-143-10-1203-b06","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jmoldx.2014.09.002","article-title":"Regulating laboratory-developed tests","volume":"16","author":"O'Leary","year":"2014","journal-title":"J Mol Diagn"},{"issue":"1","key":"2020081300265724900_i1543-2165-143-10-1203-b07","doi-asserted-by":"crossref","first-page":"13","DOI":"10.5858\/arpa.2012-0077-ED","article-title":"Food and Drug Administration approval of laboratory tests","volume":"137","author":"Allen","year":"2013","journal-title":"Arch Pathol Lab Med"},{"issue":"2","key":"2020081300265724900_i1543-2165-143-10-1203-b08","article-title":"FDA's proposed guidance for laboratory developed tests: how should regulators balance the risks and promise of innovation?","volume":"5","author":"Bayefsky","year":"2015","journal-title":"FDLIs Food Drug Policy Forum"},{"issue":"9","key":"2020081300265724900_i1543-2165-143-10-1203-b09","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1038\/nbt0914-855a","article-title":"FDA pushes for control over laboratory-developed tests","volume":"32","author":"Ratner","year":"2014","journal-title":"Nat Biotechnol"},{"key":"2020081300265724900_i1543-2165-143-10-1203-b10","article-title":"Alternative proposals for lab test regulation: are there opportunities for consensus?","author":"Ray","year":"2018"},{"key":"2020081300265724900_i1543-2165-143-10-1203-b11","article-title":"FDA's LDT proposal means \u201cwhole new ballgame\u201d for labs","author":"O'Reilly","year":"2014","journal-title":"CAP Today"},{"key":"2020081300265724900_i1543-2165-143-10-1203-b12","article-title":"ASIP response to FDA draft LDT guidance","author":"Sobel","year":"2018"},{"issue":"5","key":"2020081300265724900_i1543-2165-143-10-1203-b13","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/nbt.3221","article-title":"Precision medicine and the FDA's draft guidance on laboratory-developed tests","volume":"33","author":"Hwang","year":"2015","journal-title":"Nat Biotechnol"},{"issue":"2","key":"2020081300265724900_i1543-2165-143-10-1203-b14","first-page":"11","article-title":"A need for clarity on regulation of LDTs","volume":"29","author":"Herbek","year":"2015","journal-title":"CAP Today"},{"key":"2020081300265724900_i1543-2165-143-10-1203-b15","article-title":"The public health evidence for FDA oversight of laboratory developed tests: 20 case studies","author":"US Food and Drug Administration","year":"2018"},{"issue":"1","key":"2020081300265724900_i1543-2165-143-10-1203-b16","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jmoldx.2013.10.003","article-title":"Revisiting oversight and regulation of molecular-based laboratory-developed tests: a position statement of the Association for Molecular Pathology","volume":"16","author":"Ferreira-Gonzalez","year":"2014","journal-title":"J Mol Diagn"},{"issue":"23","key":"2020081300265724900_i1543-2165-143-10-1203-b17","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1056\/NEJMsr1501194","article-title":"The FDA and genomic tests\u2014getting regulation right","volume":"372","author":"Evans","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"2020081300265724900_i1543-2165-143-10-1203-b18","first-page":"1","article-title":"Regulatory approval for new pharmacogenomic tests: a comparative overview","volume":"66","author":"Joly","year":"2011","journal-title":"Food Drug Law J"},{"key":"2020081300265724900_i1543-2165-143-10-1203-b19","article-title":"FDA notification and medical device reporting for laboratory developed tests (LDTs): draft guidance","author":"US Food and Drug Administration (FDA)","year":"2018"},{"key":"2020081300265724900_i1543-2165-143-10-1203-b20","article-title":"CDRH'S approach to tumor profiling next generation sequencing tests","author":"US Food and Drug Administration","year":"2018"},{"key":"2020081300265724900_i1543-2165-143-10-1203-b21","article-title":"List of cleared or approved companion diagnostic devices (in vitro and imaging tools)","author":"US Food and Drug Administration (FDA)","year":"2018"},{"key":"2020081300265724900_i1543-2165-143-10-1203-b22","article-title":"FDA grants marketing approval to FoundationOne CDx in vitro diagnostic","author":"US Food and Drug Administration (FDA)","year":"2018"},{"key":"2020081300265724900_i1543-2165-143-10-1203-b23","article-title":"FDA unveils a streamlined path for the authorization of tumor profiling tests alongside its latest product action","author":"US Food and Drug Administration (FDA)","year":"2018"},{"key":"2020081300265724900_i1543-2165-143-10-1203-b24","article-title":"CMS finalizes coverage of next generation sequencing tests, ensuring enhanced access for cancer patients","author":"Centers for Medicare & Medicaid Services","year":"2018"},{"key":"2020081300265724900_i1543-2165-143-10-1203-b25","article-title":"Proposed decision memo for next generation sequencing (NGS) for Medicare beneficiaries with advanced cancer (CAG-00450N)","author":"Centers for Medicare & Medicaid Services","year":"2018"},{"issue":"6","key":"2020081300265724900_i1543-2165-143-10-1203-b26","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1001\/jamaoncol.2017.4021","article-title":"Comparison of laboratory-developed tests and FDA-approved assays for BRAF, EGFR, and KRAS Testing","volume":"4","author":"Kim","year":"2018","journal-title":"JAMA Oncol"},{"issue":"5","key":"2020081300265724900_i1543-2165-143-10-1203-b27","doi-asserted-by":"crossref","first-page":"658","DOI":"10.5858\/arpa.2016-0280-CP","article-title":"Reporting results of molecular tests: a retrospective examination of BRAF mutation reporting","volume":"141","author":"Treece","year":"2017","journal-title":"Arch Pathol Lab Med"},{"issue":"18","key":"2020081300265724900_i1543-2165-143-10-1203-b28","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1056\/NEJMoa1506583","article-title":"Targeting mutant BRAF in relapsed or refractory hairy-cell leukemia","volume":"373","author":"Tiacci","year":"2015","journal-title":"N Engl J Med"},{"issue":"8","key":"2020081300265724900_i1543-2165-143-10-1203-b29","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1056\/NEJMoa1502309","article-title":"Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations","volume":"373","author":"Hyman","year":"2015","journal-title":"N Engl J Med"},{"issue":"7","key":"2020081300265724900_i1543-2165-143-10-1203-b30","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1056\/NEJMc1215697","article-title":"V600E inhibition in anaplastic thyroid cancer","volume":"368","author":"Rosove","year":"2013","journal-title":"N Engl J Med"},{"issue":"10","key":"2020081300265724900_i1543-2165-143-10-1203-b31","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1200\/JCO.2012.44.1568","article-title":"Brainstem ganglioglioma successfully treated with vemurafenib","volume":"31","author":"Rush","year":"2016","journal-title":"J Clin Oncol"},{"issue":"20","key":"2020081300265724900_i1543-2165-143-10-1203-b32","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2012.47.6143","article-title":"Dramatic response induced by vemurafenib in a BRAF V600E-mutated lung adenocarcinoma","volume":"31","author":"Peters","year":"2013","journal-title":"J Clin Oncol"},{"issue":"2","key":"2020081300265724900_i1543-2165-143-10-1203-b33","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1742-4658.2009.07448.x","article-title":"Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer","volume":"277","author":"Mitsudomi","year":"2010","journal-title":"FEBS J"},{"issue":"5","key":"2020081300265724900_i1543-2165-143-10-1203-b34","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1097\/JTO.0000000000000504","article-title":"Epidermal growth factor receptor tyrosine kinase inhibitor treatment response in advanced lung adenocarcinomas with G719X\/L861Q\/S768I mutations","volume":"10","author":"Chiu","year":"2015","journal-title":"J Thorac Oncol"},{"issue":"2","key":"2020081300265724900_i1543-2165-143-10-1203-b35","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/JTO.0000000000000048","article-title":"Effectiveness of gefitinib against non-small-cell lung cancer with the uncommon EGFR mutations G719X and L861Q","volume":"9","author":"Watanabe","year":"2014","journal-title":"J Thorac Oncol"},{"issue":"7","key":"2020081300265724900_i1543-2165-143-10-1203-b36","first-page":"3885","article-title":"Effectiveness of tyrosine kinase inhibitors in Japanese patients with non-small cell lung cancer harboring minor epidermal growth factor receptor mutations: results from a multicenter retrospective study (HANSHIN Oncology Group 0212)","volume":"35","author":"Otsuka","year":"2015","journal-title":"Anticancer Res"},{"issue":"11","key":"2020081300265724900_i1543-2165-143-10-1203-b37","doi-asserted-by":"crossref","first-page":"3812","DOI":"10.1158\/1078-0432.CCR-10-3408","article-title":"Effectiveness of tyrosine kinase inhibitors on \u201cuncommon\u201d epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer","volume":"17","author":"Wu","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2020081300265724900_i1543-2165-143-10-1203-b38","doi-asserted-by":"crossref","first-page":"743","DOI":"10.5858\/133.5.743","article-title":"Recommended principles and practices for validating clinical molecular pathology tests","volume":"133","author":"Jennings","year":"2009","journal-title":"Arch Pathol Lab Med"},{"key":"2020081300265724900_i1543-2165-143-10-1203-b39","unstructured":"Commission on Laboratory Accreditation, ed. Molecular Pathology Checklist. Northfield, IL: College of American Pathologists;2016."},{"issue":"11","key":"2020081300265724900_i1543-2165-143-10-1203-b40","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.5858\/arpa.2012-0561-CP","article-title":"A prospective, multi-institutional diagnostic trial to determine pathologist accuracy in estimation of percentage of malignant cells","volume":"137","author":"Viray Dr.","year":"2013","journal-title":"Arch Pathol Lab Med"},{"key":"2020081300265724900_i1543-2165-143-10-1203-b41","article-title":"Next generation sequencing (NGS) methods show superior or equivalent performance to non-NGS methods on BRAF, EGFR, and KRAS proficiency testing samples","author":"Surrey","journal-title":"Arch Pathol Lab Med"}],"container-title":["Archives of Pathology &amp; Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/meridian.allenpress.com\/aplm\/article-pdf\/143\/10\/1203\/2368056\/arpa_2018-0396-cp.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/meridian.allenpress.com\/aplm\/article-pdf\/143\/10\/1203\/2368056\/arpa_2018-0396-cp.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T19:35:07Z","timestamp":1764790507000},"score":1,"resource":{"primary":{"URL":"https:\/\/aplm.kglmeridian.com\/view\/journals\/arpa\/143\/10\/article-p1203.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,10]]},"references-count":41,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2019,4,10]]},"published-print":{"date-parts":[[2019,10,1]]}},"URL":"https:\/\/doi.org\/10.5858\/arpa.2018-0396-cp","relation":{},"ISSN":["0003-9985","1543-2165"],"issn-type":[{"value":"0003-9985","type":"print"},{"value":"1543-2165","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,10]]}}}